EMA: Diabetes drugs with glargine do not raise cancer risk

06/3/2013 | Medscape (free registration)

Diabetes drugs containing insulin glargine do not appear to increase the risk of cancer in patients, the European Medicines Agency's Committee for Medicinal Products for Human Use concluded. The committee reviewed two new cohort studies as well as studies from a search of the scientific literature.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC